Explore End-to-End Drug Discovery Solutions with Frontage

​​​​​​Many investigational new drug (IND) applications fail during preclinical and clinical development due to poor pharmacokinetic properties and toxicity, resulting in high attrition rates. To address these challenges, Frontage Global Drug Discovery Services (GDDS) offers a full spectrum of in vitro ADMET assays—including metabolic stability, drug-drug interaction with P450 and transporters, permeability, protein binding, safety pharmacology panel, and hERG—ensuring that only the most promising compounds are advanced as lead candidates into pre-IND and IND-enabling in vivo safety and toxicology studies.

Building on this foundation, our fully integrated IND-enabling programs encompass general and genetic toxicology, safety pharmacology, and all affiliated analytical and bioanalytical support, enabling the collection of robust, comprehensive data packages for IND submission. From early pilot screening through IND-enabling studies and ultimately to NDA-supporting programs, we provide the expertise to design, execute, and report the studies required to meet planning and regulatory safety obligations.

Meet Our Team